Company Overview: RestorGenex Corporation

Industry News

15 Dec

RestorGenex and Diffusion Pharmaceuticals Announce Merger Agreement

–Proposed Merger Would Create an Oncology-Focused Biotechnology Company — –Combined Company Expects to Initiate Phase III Clinical Trial in GBM for Orphan Drug-Designated TSC in 2016– BUFFALO GROVE, Ill. and CHARLOTTESVILLE, Va., Dec. 15, 2015 (GLOBE NEWSWIRE) — RestorGenex Corporation (RESX) and Diffusion Pharmaceuticals LLC, a privately-held biotechnology company,...

Read more

3 Sep

RestorGenex to Present at Rodman & Renshaw Global Investment Conference

BUFFALO GROVE, Ill., Sept. 3, 2015 (GLOBE NEWSWIRE) — RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex’s CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C....

Read more

12 Aug

RestorGenex Reports Financial Results

BUFFALO GROVE, Ill., Aug. 12, 2015 (GLOBE NEWSWIRE) — RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its cash balance and financial results for the six months ended June 30, 2015. As of June 30, 2015, cash and cash...

Read more

14 Jul

RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor.

RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several...

Read more

8 Jul

OTC Markets Group Welcomes RestorGenex to OTCQX

OTC Markets Group Inc. (OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced RestorGenex Corporation (RESX), a specialty biopharmaceutical company, has qualified to trade on the OTCQX® Best Marketplace. RestorGenex begins trading today on OTCQX under the symbol “RESX.”  U.S. investors can find current financial disclosure and...

Read more

23 Jun

RestorGenex Announces Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor

RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Universita degli Studi dell’Aquila, presented data on June 22, 2015 at the XXVth National Congress of the Italian Society of Uro-Oncology, (SIUrO)...

Read more

18 Jun

RestorGenex Announces Stockholder Approval of Reincorporation in Delaware

RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced today that stockholders in an annual meeting yesterday voted to reincorporate the company in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company intends to make these regulatory filings...

Read more

16 Jun

RestorGenex CEO Featured in Equities.com Interview

RestorGenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Ed Kershen of Equities.com. During the interview, Mr. Simes provides an overview of the Company’s clinical programs, which include...

Read more

4 Jun

Restorgenex Corporation (RESX) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10

Restorgenex Corporation (RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address